Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| AstraZeneca | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To investigate the effect of dapagliflozin on the incretin sensitivity of the pancreatic beta cell.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dapagliflozin treatment | Experimental | Test incretin sensitivity after dapagliflozin treatment in type 2 diabetes patients |
|
| Normal glucose tolerance | No Intervention | Test incretin sensitivity in subjects with normal glucose tolerance |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dapagliflozin | Drug | 8 weeks treatment of dapagliflozin added to the type 2 diabetes patients with unsufficiently controlled with metformin or sulfonylurea |
|
| Measure | Description | Time Frame |
|---|---|---|
| Difference of incretin sensitivity of pancreatic beta cell measured by hyperglycemic clamp with GLP-1 and GIP infusion | Area under the curve of C-peptide level during GLP-1 infusion under hyperglycemic clamp | From 60 minutes to 120 minutes during GLP-1 infusion under hyperglycemic clamp |
| Measure | Description | Time Frame |
|---|---|---|
| First phase insulin/C-peptide response | From 0 to 10 minutes of hyperglycemic clamp | |
| Second phase insulin/C-peptide response | From 10 to 60 minutes of hyperglycemic clamp | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Young Min Cho, M.D., Ph.D. | Seoul National University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seoul National University Hospital | Seoul | 110-744 | South Korea |
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C529054 | dapagliflozin |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Area under the curve of insulin level during GLP-1 infusion under hyperglycemic clamp |
| From 60 minutes to 120 minutes during GLP-1 infusion under hyperglycemic clamp |
| Area under the curve of insulin/C-peptide level during GIP infusion under hyperglycemic clamp | From 120 minutes to 180 minutes during GIP infusion under hyperglycemic clamp |
| Difference of incretin sensitivity between diabetes patients and normal glucose tolerance subjects | Area under the curve of C-peptide level during GLP-1 infusion under hyperglycemic clamp | From 60 minutes to 120 minutes during GLP-1 infusion under hyperglycemic clamp |
| Difference of first phase insulin/C-peptide response between diabetes patients and normal glucose tolerance subjects | From 0 to 10 minutes of hyperglycemic clamp |
| Difference of second phase insulin/C-peptide response between diabetes patients and normal glucose tolerance subjects | From 10 to 60 minutes of hyperglycemic clamp |
| Difference of area under the curve of insulin level during GLP-1 infusion under hyperglycemic clamp between diabetes patients and normal glucose tolerance subjects | From 60 minutes to 120 minutes during GLP-1 infusion under hyperglycemic clamp |
| Difference of Area under the curve of insulin/C-peptide level during GIP infusion under hyperglycemic clamp between diabetes patients and normal glucose tolerance subjects | From 120 minutes to 180 minutes during GIP infusion under hyperglycemic clamp |
| D004700 | Endocrine System Diseases |